In 2023, Dr. Guo Zhigang founded Nanjing Miracle Biotech Co., Ltd.; the company is currently located in the Jiangsu Life Science and Technology Innovation Park.

Miracle Biotech is an industry-leading cell therapy innovator, dedicated to developing universal CAR-T treatments for solid tumors and commercially viable cell therapies, always adhering to the principle that "research and innovation must aim for commercialization." Miracle Biotech has a world-class cell and gene science team and a mature, efficient commercialization team. The company follows an advanced technology development approach and has independently developed the robusT® core technology platform, relying on four proprietary technologies to overcome the challenges of autologous CAR-T and develop universal CAR-T products. As of now, Miracle Biotech's UCAR-T cell therapy pipeline has made breakthroughs in autoimmune diseases and covers solid tumors and hematological cancers, with R&D progress ranking among the global leaders.

With forward-thinking innovation, Miracle Biotech is committed to developing more advanced, widely applicable, and effective immune cell therapies, providing accessible, affordable, and high-quality cell therapy products for patients worldwide.